PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30383980-7	2019	Ambroxol mitigated cisplatin inflammatory damage by inhibition of tumor necrosis factor-alpha, interleukin-1beta, and nuclear factor kappa-B and elevation of nuclear factor erythroid 2-related factor 2.	Ambroxol	0-8	interleukin 1 beta	Homo sapiens	95-112	
26872986-6	2016	Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues.	Ambroxol	10-18	interleukin 1 beta	Homo sapiens	368-390	
26872986-9	2016	In addition, we found that ambroxol dose-dependently inhibited LPS-induced increases in the mRNA expression of MUC5AC, TNF-alpha, and IL-1beta in human bronchial epithelial cell (NCI-H292) by inhibiting the Erk signaling pathway.	Ambroxol	27-35	interleukin 1 beta	Homo sapiens	134-142	
23856970-5	2014	Ambroxol (100 nM) reduced RV14 titers and cytokine concentrations of interleukin (IL)-1beta, IL-6 and IL-8 in the supernatants and RV14 RNA in the cells after RV14 infection, in addition to reducing susceptibility to RV14 infection.	Ambroxol	0-8	interleukin 1 beta	Homo sapiens	69-91